Russell Skibsted - 01 Oct 2025 Form 4 Insider Report for Processa Pharmaceuticals, Inc. (PCSA)

Role: Chief Financial Officer
Signature: /s/ Russell Skibsted by John J. Wolfel, as Attorney-in-Fact
Issuer symbol: PCSA
Transactions as of: 01 Oct 2025
Net transactions value: $0
Form type: 4
Filing time: 03 Oct 2025, 16:27:52 UTC
Previous filing: 18 Sep 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
SKIBSTED RUSSELL	Chief Financial Officer	C/O PROCESSA PHARMACEUTICALS, INC., 601 21ST STREET SUITE 300, VERO BEACH	/s/ Russell Skibsted by John J. Wolfel, as Attorney-in-Fact	02 Oct 2025	0001308105

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	PCSA	Restricted Stock Units	Award	$0	+108,000		$0.000000	108,000	01 Oct 2025	Common Stock	108,000	$0.000000	Direct	F1
transaction	PCSA	Stock Options (Right to Buy)	Award	$0	+324,000		$0.000000	324,000	01 Oct 2025	Common Stock	324,000	$0.1980	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock, following its vesting on of one-third on October 1, 2026, and one-thirty-sixth each month thereafter until fully vested on October 1, 2028.
F2	Stock options vest one-third on the first anniversary date of the grant, with the remaining options vesting ratably over the subsequent two years.